ArticleJournal for immunotherapy of cancer2023
Reactivation of low avidity tumor-specific CD8
Article in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 16 citations in OpenAlex.
- Cancers modulate processing and presentation of p53 neoantigens to evade T cell detection.Immunity · 2026Article
- FGFR pathway inhibition enhances PD-1 blockade and modulates antitumor immunity in colorectal cancer models.BMC cancer · 2026Article
- Spatiotemporal CD8Cancer science · 2026Review
- Temporal Immune and Metabolic Shifts Drive the Anti-Tumor Efficacy of Resiquimod-Loaded Nanoparticles in Peritoneal Carcinomatosis.Advanced healthcare materials · 2026Article
- Vaccine strategies for cancer prevention in Lynch syndrome: the potential of dendritic cell-based therapy.Familial cancer · 2026Review
- Flt3L-mediated tumor cDC1 expansion enhances immunotherapy by priming stem-like CD8Nature immunology · 2026Article
- Conditional T and NK cell antagonism by a giant and highly conserved orthopoxvirus virulence factor.Research square · 2026Article
- Harnessing multivalency and FcγRIIB engagement to augment anti-CD27 immunotherapy.Nature communications · 2025Article
- Tempered signal strength via low-dose MEK inhibition optimizes therapeutic performance of engineered T cells.Journal for immunotherapy of cancer · 2025Article
- Article
- CD45 sequestration lowers the signaling threshold in lymphocytes and enhances anti-tumor immunity.bioRxiv : the preprint server for biology · 2025Article
- Shp-1 regulates the activity of low-affinity T cells specific to endogenous self-antigen during melanoma tumor growth and drives resistance to immune checkpoint inhibition.Journal for immunotherapy of cancer · 2025Article
- Low-avidity T cells drive endogenous tumor immunity in mice and humans.Nature immunology · 2025Article
- Leveraging T cells for cancer immunotherapy.Immunity & inflammation · 2025Review
- Exploiting temporal aspects of cancer immunotherapy.Nature reviews. Cancer · 2024Review
- Cancer neoepitopes viewed through negative selection and peripheral tolerance: a new path to cancer vaccines.The Journal of clinical investigation · 2024Review
- Toxicity in the era of immune checkpoint inhibitor therapy.Frontiers in immunology · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundCD8
methodsCT26 models were treated with anti-PD-1 on days 3, 6 and 9 following subcutaneous tumor implantation generating variable responses during early tumor development. Tetramer staining was performed to determine the frequency and avidity of CD8
resultsTreatment success with anti-PD-1 was associated with the preferential expansion of low avidity (Tet
conclusionsTargeting subdominant T cell responses with lower avidity against pMHC affinity neoepitopes showed potential for improving PD-1 immunotherapy. Future interventions may consider expanding low avidity populations via vaccination or adoptive transfer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.